A movement to promote and conduct research on the treatment and prevention of drug-resistant tuberculosis, with a commitment to address the substantial existing gaps in our knowledge and to help provide access to an effective cure and prophylaxis of drug-resistant tuberculosis throughout the world.

more

Nearly nine million people will develop tuberculosis (TB) in the world this year; at least 500,000 of these cases will have multidrug-resistant tuberculosis (MDR-TB). Some will receive treatment. However, we know little about the best ways of treating drug-resistant TB (DR-TB) and preventing tuberculosis in people who come in contact with DR-TB patients. Lacking a strong scientific basis in prescribing treatment regimens, existing TB treatments are often ineffective. TB control efforts require new evidence-based knowledge about optimal treatment regimens, prophylaxis, and, possibly, regimens involving new TB drugs, in order to address the growing health threats of MDR-TB and extensively drug-resistant (XDR) TB.

Sign up for our monthly newsletter and review of recent literature!

To view our most recent newsletter click here!

Has compassionate use ever sunk a drug?

Click here to read a recent International Union Against Tuberculosis and Lung Disease Editorial by RESIST-TB members, Sarah McAnaw, Carole Mitnick, and Bob Horsburgh.

“New treatments for a serious disease generate understandable excitement among patients with life-threatening conditions. As pharmaceutical companies consider compassionate use of experimental drugs, one factor is commonly cited as a barrier to such use: fear that adverse events incurred by patients during Compassionate Use/Expanded Access (CU/EA) will impede regulatory approval of the drug. Such concerns stem from the obligation to report adverse events—that are serious, unexpected, and suspected to be related to the investigational drug— experienced by patients during treatment under CU/ EA programs.1 Such reports, it is feared, will damage the future of the drug, particularly since adverse events may not be related to the experimental drug and patients taking such drugs are typically sicker than the average patient.2 Existing evidence, however, does not support the notion that such events jeopardize regulatory approval.” Click here to read the article in full. 

Recent News and Announcements

REMINDER: Webinar on 2017-2018 DR-TB Working Group Survey Results

The Union and RESIST-TB invite you to join an exciting webinar on Thursday, June 7th from 08:00 – 09:00 EST (14:00 – 15:00 CET and SAST) to review the results of the 2017-2018 DR-TB Working Group Survey regarding the global rollout of the 9-month TB regimen and the use of bedaquiline and delamanid for MDR-TB […]

How attitudes to drug-resistant TB changed

The informal settlement of Khayelitsha in Cape Town is the latest site of a multi country trial that aims to transform the treatment for drug-resistant tuberculosis (DR-TB). The endTB clinic was officially opened by Doctors Without Borders (MSF) and the City of Cape Town and will test five new drug regimens in Peru, Lesotho, Kazakhstan, Georgia and South Africa. If […]

The IJTLD Features Series of RESIST-TB Articles

The International Journal of Tuberculosis and Lung Disease has released its May publication featuring RESIST-TB Steering Committee members Dr. C. Robert Horsburgh and Dr. Carole Mitnick as guest editors. The issue also features articles written by a number of RESIST-TB members and partners. Please see a full list of articles below: Community engagement for paediatric […]

WHO Response to STREAM Stage 1 Preliminary Results

“WHO issues a position statement on the continued use of the shorter MDR-TB regimen following an expedited review of the STREAM Stage 1 preliminary result. In response to several queries to the World Health Organization (WHO) from member states and other major stakeholders on the continued use of the shorter regimen for multidrug-resistant TB (MDR-TB), […]

The International Journal of Tuberculosis and Lung Disease featuring RESIST-TB Steering Committee Members

The International Journal of Tuberculosis and Lung Disease has released its May publication featuring RESIST-TB Steering Committee Members C. Robert Horsburgh and Carole Mitnick as Guest Editors. This issue also features a supplemental publication by C. Robert Horsburgh and Amita Gupta titled, “MDR-TB in Children: Back to the Basics.” The International Journal of Tuberculosis and […]

Event Calendar

Social Media